A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.
Panelists discuss how multiple pivotal clinical trials inform polycythemia vera management strategies, highlighting key findings from CYTO-PV (strict hematocrit control <45% reduces thrombosis risk fourfold), RESPONSE (ruxolitinib’s superiority over best available therapy for controlling both hematocrit and splenomegaly), MAJIC-PV (demonstrating improved event-free survival with ruxolitinib), and PROUD-PV/CONTINUATION-PV (showing ropeginterferon’s durable molecular responses compared with hydroxyurea’s diminishing effect over time).
John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Manmeet Ahluwalia, MD, MBA, FASCO, highlights genomic testing as a crucial area of current research with immediate implications for patients with brain cancer.
Panelists discuss how JAK inhibitor therapy, while effective in treating myelofibrosis and other hematologic disorders, increases the risk of skin cancers, particularly non-melanoma skin cancers, and emphasize the importance of regular screening, patient education, and preventive measures to manage this risk.
Panelists discuss how the evolution of myelofibrosis care has led to advancements in pharmacotherapy, risk stratification, and emerging therapies while highlighting ongoing unmet needs such as long-term disease control, treatment resistance, anemia and thrombocytopenia management, and the need for personalized treatment approaches.
Prof Martin Dreyling discusses the shifting treatment landscape for patients with difficult-to-treat mantle cell lymphoma.
Panelists discuss how prophylaxis against opportunistic infections is essential for patients on immunosuppressive therapy for chronic graft-vs-host disease (cGVHD).
Panelists discuss how in polycythemia vera (PV), when standard cytoreductive therapies fail to control symptoms, targeted treatments such as ruxolitinib for pruritus and splenomegaly, iron supplementation for fatigue, nonsteroidal anti-inflammatory drugs (NSAIDs) for pain, and psychosocial support play a crucial role in improving symptom management and enhancing patient quality of life.
Panelists discuss how in polycythemia vera (PV), effective management involves a dual focus on thrombosis prevention with aspirin, phlebotomy, and cytoreductive therapy, alongside strategies for managing symptoms like fatigue, pruritus, and splenomegaly, while regular assessments of quality of life and psychosocial support are essential for enhancing patient well-being.
Panelists discuss how specialists balance controlling chronic graft-vs-host disease (cGVHD) symptoms while minimizing steroid exposure when patients fail initial therapy.
Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.
Praneeth Reddy Sudalagunta, PhD, discusses a novel generative artificial intelligence pipeline developed to help with the understanding and treatment of multiple myeloma.
David Craig, PhD, discusses how AI is transforming cancer histopathology.
Mack Roach III, MD, discusses concerns about how tariffs and restrictions on international collaboration could negatively affect cancer research and treatment.
Nini Wu, MD, MBA, discusses the future of technology in community oncology, particularly highlighting the pervasive topic of artificial intelligence.
A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for treatment-resistant chronic graft-vs-host disease (cGVHD), with high response rates, durable responses, and tolerable adverse effects at the FDA-approved dose of 0.3 mg/kg every 2 weeks.
A panelist discusses how chronic graft-vs-host disease (cGVHD) is a common posttransplant complication with increasing incidence due to peripheral blood stem cell grafts, older patients, and more unrelated donor transplants, which can manifest in multiple organs and is typically treated with corticosteroids as first-line therapy.
Pedro C. Barata, MD, MSc, discusses options for metastatic hormone-sensitive prostate cancer in the community setting.
Christopher Schenewerk, MD, addresses the taboo topic of how to help health care professionals struggling with addiction.
Ariel Lopez-Chavez, MD, discusses the role of comprehensive genomic profiling in small cell lung cancer management.
Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.
Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ongoing symptoms), with experts advocating for either second-line ruxolitinib for rapid symptom and hematologic control or interferons (particularly in younger patients), while emphasizing the importance of addressing modifiable cardiovascular risk factors like smoking cessation.
A panelist discusses how first-line treatment options for neuroendocrine tumors depend on tumor grade, disease extent, and symptoms, ranging from observation for asymptomatic cases to somatostatin analogues, chemotherapy, and the newly approved cabozantinib.
Panelists discuss how polycythemia vera treatment follows a risk-stratified approach, with all patients receiving daily aspirin and phlebotomies to maintain hematocrit below 45%, while high-risk patients (aged >60 years or history of thromboembolism) additionally require cytoreductive therapy with options including hydroxyurea, pegylated interferon alfa-2a, ropeginterferon alfa-2b, or second-line ruxolitinib, with treatment modifications based on response, tolerance, and disease progression.
A panelist discusses how neuroendocrine tumors are defined by World Health Organization (WHO) classification, graded based on Ki-67 proliferative index, diagnosed through imaging (often incidentally), and most commonly found in the small bowel, lungs, and pancreas.
Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.